Retension Pharmaceuticals: Lytton reports 7.4% stake

The reported 7.4% position is measured against 8,331,599 common shares outstanding after the October 13, 2026 IPO closing.

Rhea-AI Filing Summary

Retension Pharmaceuticals, Inc. (RTSN) reporting person Laurence W. Lytton reported beneficial ownership of 617,207 common shares, equal to 7.4% of the class.

He reported sole voting and dispositive power over 617,207 shares, with no shared voting or dispositive power. The percentage was calculated using 8,331,599 common shares outstanding following the October 13, 2026 closing of the issuer’s initial public offering.

Key Figures

Beneficially owned: 617,207 shares Percent of class: 7.4% Common shares outstanding: 8,331,599 shares +2 more

5 metrics

Beneficially owned 617,207 shares Common stock

Percent of class 7.4% Based on shares outstanding following the October 13, 2026 IPO closing

Common shares outstanding 8,331,599 shares Following the October 13, 2026 closing of the initial public offering

Sole voting power 617,207 shares Reported by Laurence W. Lytton

Sole dispositive power 617,207 shares Reported by Laurence W. Lytton

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power

3 terms

beneficially owned regulatory

"Amount beneficially owned: 617,207"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power regulatory

"Sole Voting Power 617,207.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power regulatory

"Sole Dispositive Power 617,207.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RTSN shares does Laurence W. Lytton beneficially own?

Laurence W. Lytton reported beneficial ownership of 617,207 common shares. He reported sole voting and dispositive power over those shares.

What percentage of RTSN does Laurence W. Lytton own?

Laurence W. Lytton reported beneficial ownership equal to 7.4% of the class. The percentage was calculated using 8,331,599 common shares outstanding following the October 13, 2026 closing of the issuer’s initial public offering.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 03:03 PM EDT Accepted by SEC EDGAR 10/15/2026 - 03:03 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Retension Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

76135H100

(CUSIP Number)

10/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 76135H100

1

Names of Reporting Persons

Laurence W. Lytton

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 617,207.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 617,207.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

617,207.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.4 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Percentage calculated based on 8,331,599 shares of Common Stock outstanding following the closing of the Issuer's initial public offering on October 13, 2026, as reported in the Prospectus filed by the Issuer on October 9, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Retension Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 1104 West Broad Street, #1029, Falls Church, VA 22046
Item 2.
(a)	Name of person filing: Laurence W. Lytton
(b)	Address or principal business office or, if none, residence: 467 Central Park West New York, NY 10025
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 76135H100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 617,207
(b)	Percent of class: 7.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 617,207
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 617,207
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Laurence W. Lytton

Signature:	/s/ Laurence W. Lytton
Name/Title:	Reporting person
Date:	10/15/2026